Yüklüyor......
Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma
The recent FDA approval of multiple new pharmaceutical agents for metastatic renal cell carcinoma (RCC) has left physicians with several options for first- and second- line therapy. With limited head-to-head comparisons, however, there is a paucity of evidence to recommend the use of one agent over...
Kaydedildi:
| Yayımlandı: | Transl Cancer Res |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4986829/ https://ncbi.nlm.nih.gov/pubmed/27540511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tcr.2016.06.05 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|